Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis

Company Overview

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Key Stats

• Today's Range: $84.40 to $86.98
• 50-Day Range: $75.35 to $89.10
• 52-Week Range: $62.35 to $90.04
• Volume: 447,230 shs
• Average Volume: 275,168 shs
• Market Capitalization: $4.19 billion
• P/E Ratio: 19.80
• Dividend Yield: N/A
• Price Target: $93.33
• Consensus Rating: Moderate Buy

Prestige Consumer Healthcare Stock Analysis - MarketRank™

Prestige Consumer Healthcare scored higher than 81% of companies evaluated by MarketBeat, and ranked 245th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Prestige Consumer Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Prestige Consumer Healthcare has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.78%

Earnings Growth

Earnings for Prestige Consumer Healthcare are expected to grow by 5.78% in the coming year, from $4.50 to $4.76 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prestige Consumer Healthcare is 19.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prestige Consumer Healthcare is 19.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.25.

Price to Earnings Growth Ratio

Prestige Consumer Healthcare has a PEG Ratio of 2.69. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Prestige Consumer Healthcare has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.15% of the float of Prestige Consumer Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Prestige Consumer Healthcare has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Prestige Consumer Healthcare has recently increased by 1.32%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Prestige Consumer Healthcare does not currently pay a dividend.

Dividend Growth

Prestige Consumer Healthcare does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Prestige Consumer Healthcare is 44.50%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Prestige Consumer Healthcare will have a dividend payout ratio of 39.92% next year. This indicates that Prestige Consumer Healthcare will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -2.35

Percentage of Shares Shorted

3.15% of the float of Prestige Consumer Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Prestige Consumer Healthcare has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Prestige Consumer Healthcare has recently increased by 1.32%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.43

News Sentiment

Prestige Consumer Healthcare has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Prestige Consumer Healthcare this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for PBH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Prestige Consumer Healthcare to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Prestige Consumer Healthcare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,020.00 in company stock.

Percentage Held by Insiders

Only 1.60% of the stock of Prestige Consumer Healthcare is held by insiders.

Percentage Held by Institutions

99.95% of the stock of Prestige Consumer Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PBH Stock Analysis - Frequently Asked Questions

How have PBH shares performed this year?

Prestige Consumer Healthcare's stock was trading at $78.09 on January 1st, 2025. Since then, PBH shares have increased by 8.3% and is now trading at $84.5390.
View the best growth stocks for 2025 here.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its quarterly earnings results on Thursday, February, 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a trailing twelve-month return on equity of 12.36% and a net margin of 19.13%.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prestige Consumer Healthcare investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY).

Company Calendar

• Last Earnings: 2/06/2025
• Today: 4/03/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Personal Products
• Current Symbol: NYSE:PBH
• CIK: 1295947
• Web: www.prestigebrands.com
• Phone: (914) 524-6800
• Fax: 302-674-5266
• Employees: 540
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $93.33
• High Stock Price Target: $104.00
• Low Stock Price Target: $76.00
• Potential Upside/Downside: +9.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $4.27
• Trailing P/E Ratio: 19.91
• Forward P/E Ratio: 18.90
• P/E Growth: 2.69
• Net Income: $209.34 million
• Net Margins: 19.13%
• Pretax Margin: 24.82%
• Return on Equity: 12.36%
• Return on Assets: 6.39%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 3.68
• Quick Ratio: 2.20

Sales & Book Value

• Annual Sales: $1.12 billion
• Price / Sales: 3.77
• Cash Flow: $4.99 per share
• Price / Cash Flow: 17.03
• Book Value: $36.10 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 49,538,000
• Free Float: 48,745,000
• Market Cap: $4.21 billion
• Optionable: Optionable
• Beta: 0.46